Public Health Interests
Alcoholism/Alcohol; Drug Abuse/Addition; HIV/AIDS; Risky Behaviors
Dr. Springer's research interests include improving adherence to antiretrovirals and drug treatment for HIV infected men and women with co-occurring substance use disorders and mental illness. Clinical research includes relapse prevention to opioid and alcohol use using substance dependence pharmacotherapies including buprenorphine and naltrexone among HIV+ released prisoners.
Extensive Research Description
She has received a 5 year K23 Career Development Award from the National Institute of Drug Abuse (NIDA) to study adherence interventions for HIV-infected opiate dependent released prisoners providing directly observed antiretroviral therapy and buprenorphine/naloxone treatment and its effects on relapse prevention as well as HIV clinical endpoints. Dr. Springer is also a CIRA- affiliated scientist. She has 2 R01s (NIAAA and NIDA) as principal investigator to evaluate the effectiveness of extended-release naltrexone to maintain HIV treatment outcomes via preventing relapse to alcohol and opioid use among HIV+ persons leaving the criminal justice system. She is a co-investigator on 2 R01s with PI Dr. Altice from NIDA (1) using buprenorphine to improve HIV treatment outcomes among opioid dependent persons with criminal justice histories in Washington D.C. and (2) implementing extended-release naltrexone for opioid dependent persons in Ukraine. She has a K02 independent scientist award from NIDA as well. Dr. Springer has expertise in the development and implementation of medication-assisted-therapy interventions involving HIV+, drug and alcohol dependent persons involved in the criminal justice setting.
1.. The effect of alcohol pharmacotherapy (extended-release naltrexone) in a double-blind placebo-controlled randominzed trial to assess effects on relapse to alcohol use and HIV biological endpoints (CD4 count, HIV-1 Viral Load) among HIV+ alcohol dependent released prisoners.
2. Using a randomized, placebo-controlled trial, HIV treatment, opioid treatment and HIV risk behavior outcomes are examined among HIV+ prisoners with opioid dependence who are treated with injectable naltrexone as they are released to the community.
3. HIV risk reduction among persons being released from correctional settings.
4. Improving linkages to care for HIV-infected released prisoners.
5. Identification and treatment of co-occurring mental illness among HIV+ released prisoners.
6. implementing Xr-ntx among opioid dependent persons in Ukraine.
7. Evalauting the effect of buprenorphine to improve linkage to care for HIV+ opioid dependent persons with criminal justice histories in Washington D.C.
- Springer SA, Chen S, Altice FL. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care. 2009 August; 21; 8: 976-983. [PMC2797133]
- Springer SA & Bruce R. A pilot survey of attitudes and knowledge of opioid substitution therapy for HIV-infected prisoners. Journal of Opiate Management. 2008 April; 4(2): 81-86. [PMC2476214]
- Springer SA, Friedland G, Doros, G, Pesanti E, Altice F. Antiretroviral treatment regimens outcomes among HIV-Infected prisoners. HIV Clinical Trials. 2007 Jul-Aug; 8(4):205-212. [PMC2409059]
- Springer SA & Altice FL. Managing HIV in correctional settings. Current HIV/AIDS Reports. 2005 Nov; 2:165-170. [PMID: 16343373]
- Altice FL, Marinovich A, Khoshnood K, Blankenship KM, Springer SA, Selwyn PA. Correlates of HIV infection among incarcerated women: Implications for improving detection of HIV infection. Journal of Urban Health. 2005 Jun; 82(2):312-26. [PMID: 15872190
- Springer SA, Pesanti E, Doros G, Hodges J, Macura T, Altice FL. Effectiveness of antiretroviral therapy among HIV infected prisoners: Reincarceration and the lack of sustained benefit after release to the community. Clinical Infectious Diseases. 2004 Jun
- Meyer J, Wickersham J, Fu J, Brown SE, Sullivan T, Springer S, Altice F. Partner Violence and Health among HIV-Infected Jail Detainees. International Journal of Prisoner Health. Int J Prison Health. 2013; 9(3): 124–141. PMCID: PMC3873166
- Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, Jordan AO, Lincoln T, Flanigan TP, Porterfield J, Altice FL. Contribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-infected P
- Krishnan A, Wickersham JA, Chitsaz E, Springer SA, Jordan AO, Zaller N, Altice FL. Post-release substance abuse outcomes among HIV-infected jail detainees: Results from a multisite study. AIDS Behavior. 2012. Nov 11. [Epub ahead of print] [PMID: 23142854
- Di Paola A, Lincoln T, Skiest D, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitio
- Springer SA, Altice FL, Herme M, & Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community.
- Meyer J, Cepeda J, Springer S, Wu J, Trestman R, Altice F. HIV in Prison’s Revolving Door: A Longitudinal Cohort Study of Recidivists with HIV. Lancet HIV. IN PRESS
- Di Paola A, Altice FL, Powell ML, Trestman RL & Springer SA. (2014). A Comparison of Psychiatric Diagnoses Among HIV-Infected Prisoners Receiving Combination Antiretroviral Therapy Transitioning to the Community. Health and Justice. IN PRESS
- Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An Evaluation of Hepatic Enzyme Elevations Among HIV-Infected Released Prisoners Enrolled in Two Randomized Placebo-Controlled Trials of Extended Release Naltrexone. Journal of
- Meyer J, Cepeda J, Wu J, Trestman R, Altice F, Springer S. Optimization of HIV Treatment during Incarceration: Viral Suppression at the Prison Gate. JAMA Internal Medicine. 2014 Mar31. doi: 10.1001/jamainternmed.2014.601. [Epub ahead of print] [PMID: 24
- Wickersham JA, Azar MM, Cannon CM, Altice FL & Springer SA. Validation of a brief measure of opioid dependence: the rapid opioid dependence screen (RODS). Journal of Correctional Health Care. Volume 21 Issue 1 (January 2015).
- Springer SA, Dushaj A, Marwan AM. The Impact of DSM-IV Mental Disorders on Adherence to Combination Antiretroviral Therapy among Adult Persons Living with HIV/AIDS: A Systematic Review Article. AIDS Behav 2012. [Epub ahead of print] [PMID: 22644066]
- Springer SA, Qiu J, Saber-Tehrani, AS, & Altice, FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS ONE. 2012; 7(5): e38335. [PMID 22719814]
- Chen NE, Meyer JP, Avery Ak, Draine J, Ph, Flanigan TP, Lincoln T, Spaulding AC, Springer SA, Altice FL. Adherence to HIV treatment and care among previously homeless jail detainees. AIDS and Behavior, 2011; Nov 8 (Epub ahead of print).(PMID: 22065234)
- Saber Tehrani AS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, Study Design and Sample Characteristics of a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy for HIV-infected Prisoners Transitioning to the Com
- Springer SA, Spaulding AC, Meyer JP, Altice FL. Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components. Clinical Infectious Disease, 2011 53(5):469-479.
- Springer SA. A commentary: A Call to Action: Opioid Substitution Therapy as a Conduit to Routine Care and Primary Prevention of HIV Transmission Among Opioid Dependent Prisoners. Addiction. 2010; 105; 224-225. [PMC2825564]
- Springer SA, Chen S, Altice FL. Improved HIV and Substance Abuse Treatment Outcomes For Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment. Journal of Urban Health. 2010. Epub February 23, 2010. [PMC2825564]
- Springer, SA. Improving healthcare for incarcerated women: an editorial. Journal of Women’s Health. 2010 Jan; 19 (1): 13-15. [PMC2828190]